search

The first Avastin(Bevacizumab) Biosimilar approval in China granted by NMPA

ABOUT US

图片名称

The first Avastin(Bevacizumab) Biosimilar approval in China granted by NMPA


Release time:

2019-12-09

The National Medical Products Administration today approved Qilu’s Ankeda as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Ankeda is the first Avastin biosimilar approved in China for the treatment of cancer.

The NMPA’s approval of Ankeda is based on review of evidence that includes extensive structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrates Ankeda is biosimilar to Avastin.

Qilu made big investment on Ankeda development. It took less than 1.5 years for the NMPA to greenlight Qilu’s Ankeda. Qilu is committed to bringing more biosimilars to patients to help lower healthcare costs and increase access to important therapies.

 

 

齐鲁制药有限公司
齐鲁制药有限公司
齐鲁制药有限公司

 

Tel: +86-531-83127705831277048312770683127711

Address: 8888 Lvyou Road, High-tech Zone, Jinan, 250104, China

Email:export@qilu-pharma.com


监督举报

亲爱的合作伙伴:

欢迎举报以下行为!

索贿、暗箱操纵招标、内定中标单位、员工或亲属参与公司业务往来牟取私利、偷工减料、以次充好、故意刁难供应商等行为。

举报电话:0531-83126898/55820713/83126871

举报邮箱:qljc@qilu-pharma.com

收信地址:山东省济南市历城区旅游路8888号

齐鲁制药集团审计监察部

采购平台技术专线